Exosome multivalent vaccine - Capricor Therapeutics
Alternative Names: Exosome display vaccine; Exosome-SARS-CoV-2 Display Vaccine; StealthX™ vaccineLatest Information Update: 30 Mar 2026
At a glance
- Originator Capricor Therapeutics
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 13 Mar 2026 Adverse events data from a phase-I clinical trials in COVID-2019 infections released by Capricor Therapeutics
- 11 Aug 2025 Phase-I clinical trials in COVID-2019 infections (Prevention) (IM) (prior to August 2025)
- 11 Aug 2025 The US FDA approves the Investigational New Drug application (IND) for StealthX™ exosome-based vaccine for the prevention of COVID-2019 infections (prior to August 2025)